Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

FitRX, LLC dba FitRx

Has FitRx received an FDA warning letter? Yes. FDA issued a warning letter dated February 20, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
February 20, 2026 (2026-02-20)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded drug productscompounded semaglutide drug productscompounded tirzepatide drug products
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website labeling and promotion of compounded semaglutide and tirzepatide misbranded: FitRx identified as compounder though it is not, and claims implying FDA approval via comparisons to Wegovy, Ozempic, Zepbound, Mounjaro.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding — false or misleading labeling (FDCA 502(a))
  • misbranding — false or misleading advertising or promotion of compounded drugs (FDCA 502(bb))
  • implied FDA approval of unapproved compounded drugs
  • false representation that FitRx is the compounder

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.